#USA #California #Class Action #Hims Health #Hims Securities

Investor Alert: Hims & Hers Health, Inc. Class Action Lawsuit Opportunity

If you purchased Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025, and July 29, 2026, you may be entitled to participate in a class action lawsuit. The firm Kessler Topaz Meltzer & Check, LLP, has taken legal action against the company amidst allegations of fraud and misleading disclosures regarding their privacy practices.

Key Details of the Case

• - Who is involved? Hims & Hers Health, Inc. – a known name in the healthcare sector.
• - What is the nature of the lawsuit? The class action lawsuit claims material misstatements and/or omissions made by Hims, specifically regarding how the company handles consumer health data.
• - When did the alleged fraud occur? The legal claims pertain to actions during the specified period of August 4, 2025, through July 29, 2026.
• - Important deadline: Investors must file for lead plaintiff status by November 2, 2026, to be considered for leading the class action.

Allegations Against Hims & Hers Health, Inc.

The complaint filed in the United States District Court for the Northern District of California reveals serious accusations:
1. Hims is alleged to have shared consumer health information with third parties without proper disclosure.
2. Consumers were charged for prescriptions almost immediately after submitting an intake form, contrary to the company’s promise of consultation for tailored treatment solutions.
3. These actions have drawn regulatory scrutiny, impacting the company's financial and operational prospects.
4. Hims’s misleading statements about its business operations have led investors to incur financial losses following revelations about these practices.

Context of the Stock Price Decline

The situation escalated on July 29, 2026, when the Federal Trade Commission (FTC) filed its lawsuit against Hims, signaling potential regulatory troubles that significantly affected its stock. With the announcement, Hims's share price fell by $4.32, a 14.73% drop, closing at $25.00 per share. This drop underscores the impact of the lawsuit on investor sentiment.

What Should Affected Investors Do?

Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free consultation regarding their rights.

• - Options for Action: Investors have the opportunity to become lead plaintiffs if they file before the deadline. Becoming a lead plaintiff means you will represent the interests of all investors in the class action suit, which can lead to a more significant recovery if the lawsuit is successful.
• - Costs of Legal Representation: It's important to note that KTMC operates on a contingency fee basis, meaning investors won’t incur costs unless they win the case.

How to Get Involved

Receive guidance on whether to join the lawsuit by reaching out to Kessler Topaz Meltzer & Check, LLP through their website or direct contact with attorney Jonathan Naji. All inquiries can be treated confidentially without any financial obligation.

Knowing that these issues may impact your investment significantly, it's crucial for affected investors to act swiftly by reaching out to the law firm for potential recovery avenues. In the world of securities fraud, time is often of the essence.